Drug Profile
MEN 1703
Alternative Names: MEN-1703; SEL 24; SEL24 program; SEL24-1; SEL24-B489; SEL24/MEN1703Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Selvita
- Developer Menarini; Ryvu Therapeutics; Theradex
- Class Antineoplastics; Benzimidazoles; Halogenated hydrocarbons; Nitro compounds; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene proteins c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia
- Preclinical Myelofibrosis
- No development reported Lymphoma